Provectus Biopharma Reports Material Agreement and Equity Sales

TL;DR

Provectus Biopharma inked a new deal, dropped some equity, and filed financials. Watch this space.

AI Summary

On January 15, 2025, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on January 22, 2025.

Why It Matters

This 8-K filing indicates new financial obligations and equity transactions for Provectus Biopharmaceuticals, which could impact its financial structure and shareholder equity.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and unregistered sales of equity, which can introduce financial obligations and dilution risks.

Key Players & Entities

• PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Registrant
• January 15, 2025 (date) — Earliest event reported
• January 22, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $10,000,000 — o arrange for financing of a maximum of $10,000,000 (the "2025 Financing"). Pursuant to t
• $0.001 — Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock"
• $2.8620 — tstanding at a price per share equal to $2.8620; (b) The Loan is automatically conver
• $1,000,000 — ompany had received 2024 Notes totaling $1,000,000. The Company believes the issuance of

Filing Documents

• form8-k.htm (8-K) — 52KB
• ex4-1.htm (EX-4.1) — 67KB
• ex10-1.htm (EX-10.1) — 11KB
• 0001493152-25-003193.txt ( ) — 312KB
• pvct-20250115.xsd (EX-101.SCH) — 3KB
• pvct-20250115_lab.xml (EX-101.LAB) — 33KB
• pvct-20250115_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 800 S. Gay Street , Suite 1610 , Knoxville , TN 37929 (Address of Principal Executive Offices) (Zip Code) (866) 594-5999 (Registrant's Telephone Number, Including Area Code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: None Title of each class Trading Symbol(s) Name of each exchange on which registered Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01 Entry into a Material Definitive Agreement. The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On January 15, 2025, the board of directors (the "Board") of Provectus Biopharmaceuticals, Inc. (the "Company") approved a Financing Term Sheet (the "2025 Term Sheet"), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $10,000,000 (the "2025 Financing"). Pursuant to the 2025 Term Sheet, a 2025 Note (defined below) will convert into shares of the Company's Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") within twelve months of the issue date of the 2025 Note, The 2025 Financing will be obtained in several tranches. The proceeds from the 2025 Financing will be used to fund the Company's drug discovery and development program, as currently constituted and envisioned, and to fund the Company's general and administrative expenses. Structure of the Financing The 2025 Financing will be in the form of an unsecured convertible loan (the "Loan") from various investors (collectively, the "Investors") that will be evidenced by convertible promissory notes (individually, a "2025 Note" and collectively, the "2025 Notes"). In addition to customary provisions, the 2025 Note contains the following provisions: (i) The Loan will bear interest at the rate of eight percent (8%) per annum on the outstanding principal amount of the Loan that has been funded to the Company; (ii) The Loan shall be due and payable in full on the earliest of: (i) the date upon which an event of default occurs and is continuing; (ii) a change of control of the Company; or (iii) twelve months after the issue date of a 2025 Note; and (iii) The outstanding principal amount and interest payable under the Loan is convertible at the Investor's option as follows: (a) The Loan is voluntarily convertible into shares of the Company's Series D-1 Preferred Stock at any time while the Loan is outstanding at a price per share equal to $2.8620; (b) The Loan is automatically convertible into shares of the Company's Series D-1 Preferred Stock twelve months after the issue date of a 2025 Note at a price per share equal to $2.8620; and (c) The Series D-1 Preferred Stock is convertible into ten (10) shares of the Company's common stock, par value $0.001 per share; The form of the 2025 Note is attached hereto as Exhibit 4.1 and is incorporated herein by reference. The 2025 Term Sheet is attached hereto as Exhibit 10.1 and is incorporated herein by reference. 2 Closing of the 2024 Financing Pursuant to the approval of the 2025 Financing by the Board, the Board approved the closing of the financing that the Board approved on July 11, 2024 (the "2024 Financing") and that was filed with the S

View Full Filing

View this 8-K filing on SEC EDGAR